Company Northwest Biotherapeutics, Inc. Börse Stuttgart

Stocks

NBYB

US66737P6007

Biotechnology & Medical Research

Delayed Börse Stuttgart Other stock markets 14:17:26 2026-07-14 EDT			5-day change	1st Jan Change
0.1600 ^EUR	0.00%		0.00%	-22.33%

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Business description: Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Number of employees: 105

Sales by Activity: Northwest Biotherapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Discover and Develop Innovative Immunotherapies for Cancer	1M	1.68M	1.93M	1.38M	1.38M

See all business segments

Geographical breakdown of sales: Northwest Biotherapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	1M	1.68M	1.93M	1.38M	1.38M

See all geographic segments

Executive Committee: Northwest Biotherapeutics, Inc.

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	2007-05-31
Linda Powers CEO	Chief Executive Officer	71	2011-06-07
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	1999-12-31
David Innes IRC	Investor Relations Contact	-	2019-02-25

See NORTHWEST BIOTHERAPEUTICS, INC. governance

Composition of the Board of Directors: Northwest Biotherapeutics, Inc.

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	1997-12-31
Linda Powers CHM	Chairman	71	2007-05-16
Navid Malik BRD	Director/Board Member	57	2012-03-31
Joseph Black BRD	Director/Board Member	76	2016-01-26
Pat Sarma BRD	Director/Board Member	81	2024-03-17

Composition of the Board of Directors

Shareholders: Northwest Biotherapeutics, Inc.

Name	Stocks	%	Valuation
Linda Powers 1.79 %	29,411,759	1.79 %	5 M €
Pat Sarma 0.4482 %	7,365,069	0.4482 %	1 M €
Moloney Securities Asset Management LLC 0.0325 %	534,710	0.0325 %	99 991 €
Kelleher Financial Advisors LLC 0.0122 %	200,000	0.0122 %	37 400 €
Marnix Bosch 0.007859 %	129,157	0.007859 %	24 152 €

Name	Stocks	%	Valuation
Jerry Jasinowski 1.882 %	28,235	1.882 %	5 280 €

List of NORTHWEST BIOTHERAPEUTICS, INC. shareholders

Company details: Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane

20814, Bethesda

+240 497 9024

http://www.nwbio.com

address Northwest Biotherapeutics, Inc.(NBYB)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+6.05%	+3.69%	+65.28%	+89.94%	53.54B
ARGENX SE	+0.21%	-6.28%	+56.18%	+127.90%	54.18B
INSMED INCORPORATED	+0.79%	-2.29%	+8.21%	+435.22%	23.66B
BIONTECH SE	+0.78%	-3.40%	-17.95%	-15.85%	22.78B
WUXI BIOLOGICS (CAYMAN) INC.	+2.36%	+1.06%	+43.34%	-6.14%	19.54B
GENMAB A/S	-2.29%	-1.92%	+35.57%	-29.14%	17.82B
PHARMAESSENTIA CORPORATION	-4.00%	-7.88%	+175.60%	+343.60%	16.01B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.15%	-4.83%	+46.53%	+627.30%	15.37B
EXELIXIS, INC.	-0.96%	-2.28%	+22.38%	+187.67%	14.09B
Average	+0.24%	-1.47%	+48.35%	+195.61%	26.33B
Weighted average by Cap.	+1.22%	-0.46%	+49.15%	+163.84%